论文部分内容阅读
英《新科学家》第93卷第1291期(1982年)报道:当单克隆抗体由英国剑桥的米尔斯坦(Cesar Milstein)首先制成时,对它最大的希望之一是可能成为攻击癌细胞的一种“搜索和破坏”系统。后来知道他所生产的单克隆抗体不能达到这个目的,因为人体的免疫防御系统像对任何其他入侵的物质一样,把单克隆抗体当作异物加以排斥。米尔斯坦的方法是把脾细胞和小鼠癌细胞融合在一起,这样产生的杂交瘤能继续生长,无限制地产生一种特殊的抗体。为了克服机体的排斥反应,剑桥的西科勒
The New Scientist, Vol. 93, No. 1291 (1982) reported that when monoclonal antibodies were first made by Cesar Milstein in Cambridge, England, one of the greatest hopes for it was that they could become cancer cells A “search and destruction” system. He later learned that the monoclonal antibodies he produced did not do so because the body’s immune defenses rejected the monoclonal antibodies as foreign bodies, just like any other invading substance. Millstone’s method is to fuse spleen cells and mouse cancer cells, so that the resulting hybridomas can continue to grow, producing a unique antibody without restriction. To overcome the rejection of the body, West Keller of Cambridge